Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESSENCE study of tezepelumab in chronic rhinosinusitis with nasal polyposis
2024-513862-20-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by AstraZeneca. Primary endpoints: Change from baseline in nasal congestion score and Change from baseline in SNOT-22 total score. Planned start Mar 2025; status: authorised.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-513862-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513862-20-00.